M. Susan Podlogar's most recent trade in LivaNova PLC was a trade of 2,355 Ordinary Shares done . Disclosure was reported to the exchange on Dec. 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| LivaNova PLC | Susan M. Podlogar | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2025 | 2,355 | 2,355 (0%) | 0% | 0 | Ordinary Shares | |
| LivaNova PLC | Susan M. Podlogar | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2025 | 2,355 | 0 | - | - | Restricted Stock Units | |
| LivaNova PLC | Susan M. Podlogar | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.06 per share. | 15 Dec 2025 | 269 | 2,086 (0%) | 0% | 63.1 | 16,963 | Ordinary Shares |
| LivaNova PLC | Susan M. Podlogar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2025 | 4,042 | 4,042 | - | - | Restricted Stock Units | |
| Tevogen Bio Holdings Inc | Susan M. Podlogar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2024 | 240,000 | 433,923 | - | 0 | Common Stock | |
| LivaNova PLC | Susan M. Podlogar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2024 | 2,355 | 2,355 | - | - | Restricted Stock Units | |
| MetLife | Susan M. Podlogar | EVP & Chief HR Officer | 01 Mar 2024 | 1,907 | 79,794 (0%) | 0% | 69.7 | 132,975 | Common Stock | |
| MetLife | M. Susan Podlogar | EVP & Chief HR Officer | 27 Feb 2024 | 26,968 | 95,523 (0%) | 0% | - | Common Stock | ||
| MetLife | Podlogar Susan M. | EVP & Chief HR Officer | 27 Feb 2024 | 13,822 | 81,701 (0%) | 0% | 69.2 | 955,930 | Common Stock | |
| MetLife | M. Susan Podlogar | EVP & Chief HR Officer | 27 Feb 2024 | 12,040 | 12,040 | - | - | Employee Stock Options (right to buy) | ||
| MetLife | M. Susan Podlogar | EVP & Chief HR Officer | 27 Feb 2024 | 4,013 | 68,555 (0%) | 0% | - | Common Stock | ||
| Tevogen Bio Holdings Inc | Susan M. Podlogar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 193,923 | 193,923 | - | - | Common Stock | |
| MetLife | Susan M. Podlogar | EVP & Chief HR Officer | 28 Feb 2023 | 29,893 | 79,746 (0%) | 0% | - | Common Stock | ||
| MetLife | Susan M. Podlogar | EVP & Chief HR Officer | 28 Feb 2023 | 13,223 | 66,523 (0%) | 0% | 71.7 | 948,486 | Common Stock | |
| MetLife | Susan M. Podlogar | EVP & Chief HR Officer | 28 Feb 2023 | 10,979 | 10,979 | - | - | Employee Stock Options (right to buy) | ||
| MetLife | Susan M. Podlogar | EVP & Chief HR Officer | 28 Feb 2023 | 3,660 | 49,853 (0%) | 0% | - | Common Stock | ||
| MetLife | Susan M. Podlogar | EVP & Chief HR Officer | 28 Feb 2023 | 1,981 | 64,542 (0%) | 0% | 71.3 | 141,186 | Common Stock | |
| MetLife | Susan M. Podlogar | EVP & Chief HR Officer | 20 Dec 2022 | 3,000 | 46,193 (0%) | 0% | 71.9 | 215,730 | Common Stock | |
| MetLife | Susan M. Podlogar | EVP & Chief HR Officer | 01 Mar 2022 | 2,056 | 49,193 (0%) | 0% | 64.4 | 132,489 | Common Stock | |
| MetLife | Susan M. Podlogar | EVP & Chief HR Officer | 22 Feb 2022 | 26,582 | 62,687 (0%) | 0% | - | Common Stock | ||
| MetLife | Susan M. Podlogar | EVP & Chief HR Officer | 22 Feb 2022 | 11,438 | 51,249 (0%) | 0% | 69.0 | 788,764 | Common Stock | |
| MetLife | Susan M. Podlogar | EVP & Chief HR Officer | 22 Feb 2022 | 10,766 | 10,766 | - | - | Employee Stock Options (right to buy) | ||
| MetLife | Susan M. Podlogar | EVP & Chief HR Officer | 22 Feb 2022 | 3,590 | 36,105 (0%) | 0% | - | Common Stock |